

Program Operations Manual System (POMS)

Effective Dates: 08/25/2020 - Present

Previous | Next TN 32 (08-20)

DI 23022.840 Obliterative Bronchiolitis

that occurs when the small alrway branches of the lungs (bronchioles) are compressed a narrowed by scart issue (fibrosis) and inflammation. Extensive scarring results in decreas lung function. Causes of OB include collagen vascular diseases, especially rheumatoid arthritis, organ transplant rejection, viral infections, drug reactions, prematurity complicat, oral emergency medicines (for example, activated charcoal), exposure to toxic fumes (I) example, diacetyl, sulfur dioxide, ammonia, chlorine, mustard gas, ozone), and idiopathic known cause). Symptoms of OB include coughing (usually without phlegm), shortness or breath on exertion, wheezing and fatigue. OB is not the same disorder as bronchibilitis obliterans organizing pneumonia (BOOP), nr known as cryptogenic organizing pneumonia (COP), which is a treatable disorder with a favorable prognosis. OB is also a distinctly different disorder than pediatric bronchiolitis, is a very common childhood respiratory illness with a good prognosis. DIAGNOSTIC Diagnostic testing: Although a definitive diagnosis include: FINDINGS, AND ICO- 9-CM/ICD-10-CM Diagnostic testing: Although a definitive diagnosis include: FINDINGS, AND ICO- 9-CM/ICD-10-CM Lung volume measurements showing an elevated residual volume and chest x-ray wi evidence of hyperinflation; • High resolution computerized tomography (CT) of the chest at full inspiration and expiration showing evidence of heterogeneous air trapping, mosaic attenuation, bron wall thickening, cylindrical bronchictasis, or scattered ground glass opacities; and • Spirometry which typically shows alrway obstruction that is generally unresponsive to bronchodilators. A restrictive pattern may be seen in some cases. Physical fin	OBLITERATIVE BRONCHIOLITIS		
that occurs when the small airway branches of the lungs (bronchioles) are compressed a narrowed by scar tissue (fibrosis) and inflammation. Extensive scaring results in decreas lung function. Causes of OB include collagen vascular diseases, especially rheumatiol arthritis, organ transplant rejection, viral infections, frug reactions, prematury complice , oral emergency medicines (for example, activated charcoal), exposure to toxic fumes (i example, diacety), sultra dioxide, ammonia, chlorine, mustard gas, core), and idoption known cause). Symptoms of OB include coupling (usually without phlegm), shortness of breath on exertion, wheezing and fatigue, OB is not the same disorder as bronchiolitis obliterans organizing pneumonia (BOOP), no known as cryptogenic organizing pneumonia (COP), which is a treatable disorder with a favorable prognosis. OB is also a distinctly different disorder than pediatric bronchiolitis, is a very common childhood respiratory illness with a good prognosis. DIAGONOSTIC TESTING, PHYSICAL ENDINGS, AND ICD- 9-CM/CD-10-CM CODINO Diagnostic testing: Although a definitive diagnosis include: Lung volume measurements showing an elevated residual volume and chest x-ray will evidence of hyperinflation; Lung volume measurements showing an elevated residual volume and chest x-ray will evidence of hyperinflation; Spirometry which typically shows airway obstruction that is generally unresponsive to bronchodilators. A restrictive pattern may be seen in some cases. Physical findings: Dry cough; Shortness of breath, and Fatigue and wheezing in the absence of a cold or asthma. Prooression The progression OC 9 varies from person to person with symptoms starting eithe	ALTERNATE NAMES	Bronchiolitis Obliterans; Constrictive Bronchiolitis	
known as cryptogenic organizing pneumonia (COP), which is a treatable disorder with a favorable prognosis. OB is also a distinctly different disorder than pediatric bronchiolitis, is a very common childhood respiratory illness with a good prognosis. DIACNOSTIC Diagnostic testing: Although a definitive diagnosis of OB requires can only made by a lubiopsy, other diagnostic tests which aid in the diagnosis include: FINDINGS, AND ICD-9-CM/CD-10-CM - Lung volume measurements showing an elevated residual volume and chest x-ray wievidence of hyperinflation; - High resolution computerized tomography (CT) of the chest at full inspiration and expiration showing evidence of heterogeneous air trapping, mosaic attenuation, brom wall thickening, cylindrical bronchiectasis, or scattered ground glass opacities; and - Spirometry which typically shows airway obstruction that is generally unresponsive to bronchodilators. A restrictive pattern may be seen in some cases. Physical findings: - Dry cough; - Shortness of breath; and - Fatigue and wheezing in the absence of a cold or asthma. ICD-9: 491.8 ICD-10: J44.9 PROGRESSION The progression of OB varies from person to person with symptoms starting either gradu suddenly. Two to eight weeks after a respiratory liness or exposure to toxic fumes, dry shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe com may require a lung transplant. Post-lung transplantation, OB continues to be a major life transplantation. TREATMENT There is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation,	DESCRIPTION	arthritis, organ transplant rejection, viral infections, drug reactions, prematurity complications , oral emergency medicines (for example, activated charcoal), exposure to toxic fumes (for example, diacetyl, sulfur dioxide, ammonia, chlorine, mustard gas, ozone), and idiopathic (no known cause). Symptoms of OB include coughing (usually without phlegm), shortness of breath on exertion, wheezing and fatigue,	
TESTING, PHYSICAL biopsy, other diagnostic tests which aid in the diagnosis include: FINDINGS, AND ICD- 9-CM/ICD-10-CM . Lung volume measurements showing an elevated residual volume and chest x-ray will evidence of hyperinflation; • High resolution computerized tomography (CT) of the chest at full inspiration and expiration showing evidence of heterogeneous air trapping, mosaic attenuation, brom wall thickening, cylindrical bronchiectasis, or scattered ground glass opacities; and • Spirometry which typically shows airway obstruction that is generally unresponsive to bronchodilators. A restrictive pattern may be seen in some cases. Physical findings: • Dry cough; • Shortness of breath; and • Fatigue and wheezing in the absence of a cold or asthma. ICD-19: J44.9 PROGRESSION The progression of OB varies from person to person with symptoms starting either gradd suddenly. Two to eight weeks after a respiratory illness or exposure to toxic fumes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe crimary require a lung transplant. Post-lung transplantation, OB continues to be a major life: threatening complication, affecting up to 50% of people who survive five years after transplantation. TREATMENT There is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are		known as cryptogenic organizing pneumonia (COP), which is a treatable disorder with a favorable prognosis. OB is also a distinctly different disorder than pediatric bronchiolitis, whic	
CODING • Lung volume measurements showing an elevated residual volume and crest X-ray we evidence of hyperinflation; • High resolution computerized tomography (CT) of the chest at full inspiration and expiration showing evidence of heterogeneous air trapping, mosaic attenuation, bron wall thickening, cylindrical bronchiectasis, or scattered ground glass opacities; and • Spirometry which typically shows airway obstruction that is generally unresponsive to bronchodilators. A restrictive pattern may be seen in some cases. Physical findings: • Dry cough; • Shortness of breath; and • Fatigue and wheezing in the absence of a cold or asthma. ICD-9: 491.8 ICD-10: J44.9 PROGRESSION The progression of OB varies from person to person with symptoms starting either gradu suddenly. Two to eight weeks after a respiratory illness or exposure to toxic furmes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe carmay require a lung transplant. Post-lung transplantation, OB continues to be a major life-threatening complication, affecting up to 50% of people who survive five years after transplantation. TREATMENT There is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are	TESTING, PHYSICAL	Diagnostic testing: Although a definitive diagnosis of OB requires can only made by a lung biopsy, other diagnostic tests which aid in the diagnosis include:	
expiration showing evidence of heterogeneous air trapping, mosaic attenuation, bron wall thickening, cylindrical bronchiectasis, or scattered ground glass opacities; and • Spirometry which typically shows airway obstruction that is generally unresponsive to bronchodilators. A restrictive pattern may be seen in some cases. Physical findings: • Dry cough; • Shortness of breath; and • Fatigue and wheezing in the absence of a cold or asthma. ICD-9: 491.8 ICD-10: J44.9 PROGRESSION The progression of OB varies from person to person with symptoms starting either gradd suddenly. Two to eight weeks after a respiratory illness or exposure to toxic fumes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe carmay require a lung transplant. Post-lung transplantation, OB continues to be a major life: threatening complication, affecting up to 50% of people who survive five years after transplantation. TREATMENT There is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are	9-CM/ICD-10-CM CODING		
bronchodilators. A restrictive pattern may be seen in some cases. Physical findings: • Dry cough; • Shortness of breath; and • Fatigue and wheezing in the absence of a cold or asthma. ICD-9: 491.8 ICD-10: J44.9 PROGRESSION The progression of OB varies from person to person with symptoms starting either gradu suddenly. Two to eight weeks after a respiratory illness or exposure to toxic furmes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe carmay require a lung transplant. Post-lung transplantation, OB continues to be a major life-threatening complication, affecting up to 50% of people who survive five years after transplantation. TREATMENT There is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are		expiration showing evidence of heterogeneous air trapping, mosaic attenuation, bronchial	
 Dry cough; Dry cough; Shortness of breath; and Fatigue and wheezing in the absence of a cold or asthma. ICD-9: 491.8 ICD-10: J44.9 PROGRESSION The progression of OB varies from person to person with symptoms starting either gradu suddenly. Two to eight weeks after a respiratory illness or exposure to toxic fumes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe carray require a lung transplant. Post-lung transplantation, OB continues to be a major lifethreatening complication, affecting up to 50% of people who survive five years after transplantation. TREATMENT There is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are 			
 Shortness of breath; and Fatigue and wheezing in the absence of a cold or asthma. ICD-9: 491.8 ICD-10: J44.9 PROGRESSION The progression of OB varies from person to person with symptoms starting either grade suddenly. Two to eight weeks after a respiratory illness or exposure to toxic fumes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe carmay require a lung transplant. Post-lung transplantation, OB continues to be a major life-threatening complication, affecting up to 50% of people who survive five years after transplantation. TREATMENT There is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are 		Physical findings:	
 Fatigue and wheezing in the absence of a cold or asthma. ICD-9: 491.8 ICD-10: J44.9 PROGRESSION The progression of OB varies from person to person with symptoms starting either graded suddenly. Two to eight weeks after a respiratory illness or exposure to toxic fumes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe carmay require a lung transplant. Post-lung transplantation, OB continues to be a major lifet threatening complication, affecting up to 50% of people who survive five years after transplantation. TREATMENT There is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are 		Dry cough;	
ICD-9: 491.8 ICD-10: J44.9 PROGRESSION The progression of OB varies from person to person with symptoms starting either gradus suddenly. Two to eight weeks after a respiratory illness or exposure to toxic fumes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe carmay require a lung transplant. Post-lung transplantation, OB continues to be a major life-threatening complication, affecting up to 50% of people who survive five years after transplantation. TREATMENT There is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are		Shortness of breath; and	
ICD-10: J44.9PROGRESSIONThe progression of OB varies from person to person with symptoms starting either graded suddenly. Two to eight weeks after a respiratory illness or exposure to toxic fumes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe car may require a lung transplant. Post-lung transplantation, OB continues to be a major life- threatening complication, affecting up to 50% of people who survive five years after transplantation.TREATMENTThere is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are		Fatigue and wheezing in the absence of a cold or asthma.	
PROGRESSIONThe progression of OB varies from person to person with symptoms starting either gradule suddenly. Two to eight weeks after a respiratory illness or exposure to toxic fumes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe carries any require a lung transplant. Post-lung transplantation, OB continues to be a major life-threatening complication, affecting up to 50% of people who survive five years after transplantation.TREATMENTThere is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are			
suddenly. Two to eight weeks after a respiratory illness or exposure to toxic fumes, dry or shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe ca may require a lung transplant. Post-lung transplantation, OB continues to be a major life- threatening complication, affecting up to 50% of people who survive five years after transplantation. TREATMENT There is currently no cure for OB. Bronchodilators, inhaled corticosteroids, oxygen supplementation, and, in the case of lung transplantation, immunosuppressants, are			
supplementation, and, in the case of lung transplantation, immunosuppressants, are	PROGRESSION	suddenly. Two to eight weeks after a respiratory illness or exposure to toxic fumes, dry cough shortness of breath (especially on exertion), fatigue, and wheezing may occur. Severe cases may require a lung transplant. Post-lung transplantation, OB continues to be a major life- threatening complication, affecting up to 50% of people who survive five years after	
	TREATMENT	supplementation, and, in the case of lung transplantation, immunosuppressants, are	
SUGGESTED PROGRAMMATIC ASSESSMENT*		SUGGESTED PROGRAMMATIC ASSESSMENT*	
Suggested MER for Evaluation:	Suggested MER for Ev	aluation:	

- Biopsy reports;
- CT scans;
- Pulmonary function tests (PFTs) including diffusing capacity of the lungs for carbon monoxide (DLCO) tests, spirometry, and arterial blood gas (ABG) tests; and
- Response, if any, to a regimen of treatment.

Suggested Listings for Evaluation:				
DETERMINATION	LISTING	REMARKS		
Meets	3.02	A description of findings establishing the diagnosis and response to treatment is needed when evaluating this condition.		
	103.02	A description of findings establishing the diagnosis and response to treatment is needed when evaluating this condition.		
Equals				
2		use the Medical Evidence of Record or the listings suggested to evaluate the r deny the claim rests with the adjudicator.		

To Link to this section - Use this URL: http://policy.ssa.gov/poms.nsf/lnx/0423022840 DI 23022.840 - Obliterative Bronchiolitis - 08/25/2020 Batch run: 08/25/2020 Rev:08/25/2020

Accessibility FOIA Open Government Glossary Privacy Report Fraud, Waste or Abuse Site Map Website Policies

This website is produced and published at U.S. taxpayer expense.